Study Title

Prospective Cohort Study Evaluating 18FDG-PET for the Early Prediction of Efficacy of Immunotherapy Combined with Chemotherapy in Patients with Non-Small Cell Non-Small Cell Broncho-Pulmonary Carcinoma or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Study Details

Description:

The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.

Sponsor:

Centre Antoine Lacassagne

Contacts:

Study Coordinator

drci-promotion@nice.unicancer.fr

04 92 03 14 76 ext +33

Government Study Link:

NCT06833229 - Click here to see study on

ClinicalTrials.gov

Drug Details

18FDG
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • Glucose Transport
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468